Health Canada says it has updated labelling for the AstraZeneca and COVISHIELD vaccines to provide information on “very rare” reports of blood clots associated with low levels of blood platelets following immunization with the AstraZeneca vaccine in parts of Europe.
The federal agency says it has been working with European regulators to review the evidence. The agency also says it is consulting with scientific experts in Canada and internationally to discuss the clotting issues – and – continues to be in contact with international regulators and the manufacturer. It has also issued guidance for healthcare professionals and vaccine recipients on potential symptoms to monitor.
Health Canada says it has not received any reports of blood clotting issues from across the country. The agency says minor and temporary discomfort such as headache – fever – fatigue – or pain at the point of injection are common after all injections. But you should seek medical attention if you experience any new or worsening symptoms. You can report any adverse effects to your healthcare professional and here.
The agency says the AstraZeneca COVID vaccine continues to be safe and effective at protecting you against COVID-19 and is encouraging you to get immunized with any of the vaccines authorized in Canada.